Insider buying last 90 days
No open-market insider purchases were filed for REGN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every REGN insider filing, plotted on the chart in Gekko.Open REGN in Gekko
NASDAQ: REGN
Regeneron Pharmaceuticals (REGN) Stock Analysis & Forecast
$784.85−4.60 (−0.6%)
Close on Sep 18, 2026. Page updated Sep 19, 9:15 pm ET.
Gekko Brief
AI summaryRegeneron (REGN) closes at $784.85, down 0.6%, holding above both its 50-day ($763.57) and 200-day ($733.80) moving averages. The GekkoIndex reads 60.6, placing the stock in the Accumulation zone. Shares trade 34.1% below Gekko Fair Value of $1,190.42. Over the past year the stock is up 34%, though the past month shows a 6.7% decline against a 52-week high of $859.34 and low of $541.00.
This week's coverage centers on federal securities class action lawsuits filed in September 2026 alleging misleading disclosures tied to the Phase III Fianlimab Libtayo oncology trial, with law firms including Schall, Brown & Schwartz and Hagens Berman flagging deadlines for investors. Separately, Regeneron presented at the Morgan Stanley Global Healthcare Conference, where management pointed to Dupixent growth, EYLEA HD commercial momentum, and cemdisiran pipeline catalysts. A comparison piece contrasted REGN with Novo Nordisk on competitive and pricing dynamics. One filing showed Corient Private Wealth LP trimming its REGN stake by 31.0%.
Looking ahead, Regeneron's next earnings report is set for 28 October 2026, 38 days out and beyond a typical 20-trading-day hold. In the last 90 days, Congressional activity shows 1 buy and 0 sells. Seasonality is a headwind: over the past 5 years, the 20 trading days following this date averaged a 5.2% decline, rising in only 2 of those years. Analyst coverage from 19 firms shows 12 buy and 7 hold ratings, with a consensus target of $849.32.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $784.85200-day averageGekko Fair Value $1,190.42
Key stats
- Market cap
- $80.86B
- P/E ratio
- 19.2
- Forward P/E
- 14
- EPS, TTM
- $41.21
- Revenue, TTM
- $15.53B
- Profit margin
- 27.9%
- Dividend yield
- 0.47%
- Beta
- 0.19
- Volume
- 2.46M avg 670,135
- 1-year return
- +34.0%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±5%
- 50-day average
- $763.57
- 200-day average
- $733.80
- Next earnings
- Oct 28 before open
- Shares outstanding
- 101.1M
Regeneron Pharmaceuticals swing-trade checklist
Regeneron Pharmaceuticals scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $784.85 is above the 50-day ($763.57) and 200-day ($733.80) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexsupportive
60.6, Accumulation
Reading 60.6 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
34.1% below
Price is 34.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 38 days
Next report Oct 28, 2026, 38 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−5.2% on average
From this point in the calendar, the next 20 trading days averaged −5.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Regeneron Pharmaceuticals stock chart and price history
Regeneron Pharmaceuticals closed at $784.85 on Sep 18, 2026, +34.0% over the past year, inside a 52-week range of $541.00 to $859.34.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −6.7%
- 3 months
- +28.7%
- 6 months
- +6.4%
- 1 year
- +34.0%
The full REGN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open REGN in Gekko
Follow Regeneron Pharmaceuticals through every session
Put REGN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track REGN in GekkoFree for 7 days. No credit card required.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals develops medicines that treat serious health conditions, spanning eye disease, immune and allergic disorders, cancer, infectious disease and rare conditions. Its treatments reach patients through injectable and infused therapies for conditions such as macular degeneration, atopic dermatitis, asthma, skin cancer, high cholesterol, rheumatoid arthritis, Ebola infection and periodic fever syndromes, among others. The company is perhaps best recognized for its work in eye care and immune-related treatments, alongside its broader pipeline of experimental drugs still in development.
Much of its business runs through partnerships rather than solely independent efforts, with collaboration and licensing arrangements involving other pharmaceutical companies and research organizations, as well as government health bodies. These relationships support both the commercialization of approved treatments and ongoing research into new drug candidates across multiple disease areas.
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, New York. Its shares are listed on the NASDAQ under the ticker REGN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- regeneron.com
Regeneron Pharmaceuticals GekkoIndex: the smart money zone
Regeneron Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.6, in the Accumulation zone, up 1.4 points over five sessions.
60.6Accumulation
Up 1.4 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 66 | −1.1% | −4.3% | ||
| Accumulation (current zone) | 197 | 0.0% | −1.8% | ||
| Neutral | 351 | +0.1% | +1.4% | ||
| Distribution | 47 | +1.1% | +3.2% | ||
| Selling | 1 | Too few readings yet | |||
Average REGN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the REGN price, zone by zone.Track REGN in Gekko
Is Regeneron Pharmaceuticals stock overvalued? Gekko Fair Value
Regeneron Pharmaceuticals trades 34.1% below Gekko Fair Value of $1,190.42, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Regeneron Pharmaceuticals shares are worth, recalculated every trading day.
$1,190.42
Gekko Fair Value, Sep 19, 2026
34.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open REGN in Gekko
Regeneron Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Regeneron Pharmaceuticals, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Aug 12 traded Jul 7 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Regeneron Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.17B
- As a share of market cap
- 1.45%
- Trailing four quarters
- $3.30B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds REGN.
1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Regeneron Pharmaceuticals earnings: next date and track record
Regeneron Pharmaceuticals reports on Oct 28, 2026, before the open (38 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected before the open, 38 days away
- EPS estimate
- $15.99
- Revenue estimate
- $4.54B
7 of 8reports beat the EPS estimate
±6%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Regeneron reported a strong Q2 2026 with total revenues up 17% year-over-year and non-GAAP EPS up 11%. Key commercial drivers were Dupixent (Sanofi-reported $6B, +38% YoY), EYLEA HD (U.S. growth and strong physician uptake), and Libtayo. Management highlighted multiple pipeline catalysts: cemdisiran regulatory submissions (FDA target action date in November 2026 for gMG), expected registrational PNH data for the pozelimab + cemdisiran combination in Q4 2026, exploratory GA C5 data due Q4 2026, and ongoing work on obesity (GLP + Praluent combination) and other I&I programs. Financial commentary emphasized repayment of the Sanofi development balance, which reduced reported collaboration revenue in 2025 and H1 2026 but will cause a step-up in Sanofi collaboration revenue starting in Q3 2026 as Regeneron records full share of collaboration profits. Management reiterated disciplined capital allocation (internal R&D focus, opportunistic M&A) and active commercialization planning for potential launches (e.g., cemdisiran). The call mixed strong commercial execution and pipeline optimism with cautious notes on regulatory timelines, a recent oncology trial near-miss (fianlimab), and ongoing manufacturing/regulatory interactions (EYLEA HD).
- Guidance
- • Cemdisiran (gMG): FDA target action date in November 2026; EMA decision anticipated H2 2027. • PNH (pozelimab + cemdisiran): Registrational data expected Q4 2026. • GA (C5 approach): 26-week exploratory cohort data expected Q4 2026 to inform pivotal strategy. • EYLEA HD prefilled syringe: ongoing FDA review with goal/hope for approval by year-end 2026 (timing not guaranteed). • Sanofi collaboration revenue: expected step-up starting Q3 2026 as Sanofi development balance has been fully repaid and Regeneron will record full share of collaboration profits. • Obesity/GLP + Praluent: Phase III program initiation expected over the next few months (H2 2026). • No new numeric revenue or EPS guidance was issued on the call beyond the directional expectation for Sanofi collaboration revenue; management reiterated focus on R&D investment and potential share repurchases/M&A but provided no specific numerical forward financial targets.
- Risks flagged
- • Regulatory timing and uncertainty (FDA reviews for cemdisiran and EYLEA HD; approvals are not guaranteed). • Clinical trial risk (fianlimab missed primary endpoint; need to demonstrate long-term benefits and safety for new modalities). • Manufacturing/CMC and supply risks (EYLEA HD prefilled syringe CMO approvals and need for multiple contract manufacturers). • Competitive pressure (GLP uptake in obesity, FcRn therapies and other entrants in gMG/PNH). • Safety/long-term risk for mechanism-related immunosuppression (concerns around complete complement blockade and FcRn approaches). • Commercial execution risk (launch execution for cemdisiran and other pipeline products).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $12.53 est $8.00 | $4.29B est $3.82B | +9.7% |
| Apr 29, 2026 | $9.47 est $9.16 | $3.61B est $3.48B | −3.4% |
| Jan 30, 2026 | $11.44 est $10.52 | $3.88B est $3.81B | +0.7% |
| Oct 28, 2025 | $11.83 est $9.65 | $3.75B est $3.59B | +11.5% |
| Aug 1, 2025 | $12.89 est $8.43 | $3.68B est $3.29B | +4.8% |
| Apr 29, 2025 | $8.22 est $8.62 | $3.03B est $3.25B | −2.0% |
| Feb 4, 2025 | $12.07 est $11.21 | $3.79B est $3.74B | +7.5% |
| Oct 31, 2024 | $12.46 est $11.69 | $3.72B est $3.67B | −8.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Regeneron Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Regeneron Pharmaceuticals is $849.32, +8.2% from the last close, from 19 firms rating the stock in the last 90 days.
$849.32consensus 12-month target, +8.2% from the last close
Now $784.85Avg $849.32
Low $737High $1,030
Each firm’s latest rating in the last 90 days: 19 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 10 | HSBC | $920 | +17.2% |
| Sep 10 | RBC Capital | $737 | −6.1% |
| Sep 1 | RBC Capital | $737 | −6.1% |
| Aug 20 | Scotiabank | $770 | −1.9% |
| Aug 17 | BMO Capital | $800 | +1.9% |
−1.8%average 20-day move after past Accumulation readings
−5.2%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Regeneron Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Regeneron Pharmaceuticals averaged −5.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.4% | 0 of 5 |
| Next 10 trading days | −4.2% | 2 of 5 |
| Next 15 trading days | −5.7% | 1 of 5 |
| Next 20 trading days | −5.2% | 2 of 5 |
| Next 30 trading days | −2.2% | 2 of 5 |
For scale, REGN’s typical 20-trading-day move in either direction is about 5%.
Regeneron Pharmaceuticals market cap and key statistics
Regeneron Pharmaceuticals’s market cap is $80.86B, with a P/E ratio of 19.2 and revenue of $15.53B over the last twelve months.
Valuation
- Market cap
- $80.86B
- P/E ratio
- 19.2
- Forward P/E
- 14
- EPS, TTM
- $41.21
- Gekko Fair Value
- $1,190.42
Trading
- Volume
- 2.46M
- Avg volume, 20 days
- 670,135
- 52-week high
- $859.34
- 52-week low
- $541.00
- Shares outstanding
- 101.1M
Financials
- Revenue, TTM
- $15.53B
- Profit margin
- 27.9%
- Return on equity
- 14%
- Quarterly earnings growth, YoY
- −4.5%
Risk and income
- Beta
- 0.19
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±5%
- Dividend yield
- 0.47%
Regeneron Pharmaceuticals stock news this week
Coverage of Regeneron Pharmaceuticals this week reads negative: 0 positive, 1 neutral and 11 negative headlines.
- How Investors Are Reacting To Regeneron Pharmaceuticals Stock (REGN) Trial Disclosure LawsuitsSimply Wall Street, Sep 18
- Corient Private Wealth LP Sells 5,600 Shares of Regeneron Pharmaceuticals, Inc. $REGNDefense World, Sep 18
- Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitorsMarketWatch, Sep 15
- REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawGlobeNewswire, Sep 15
- Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?Fool - Investing News, Sep 15
- Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD MomentumMarketBeat, Sep 14
Regeneron Pharmaceuticals peers
Regeneron Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| PFEPfizer | Neutral | 9.8% below |
A peer links to its own page where one exists.
Regeneron Pharmaceuticals stock FAQ
What is Regeneron Pharmaceuticals’s market cap?
Regeneron Pharmaceuticals’s market cap is $80.86B at the Sep 18, 2026 close of $784.85, with 101.1M shares outstanding. The shares trade on a P/E ratio of 19.2.
What is the Regeneron Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Regeneron Pharmaceuticals is $849.32, +8.2% from the last close. Of the 19 firms that rated the stock in the last 90 days, 12 rate it a buy, 7 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Regeneron Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Regeneron Pharmaceuticals is undervalued: the Sep 18, 2026 close of $784.85 is 34.1% below Gekko Fair Value of $1,190.42. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Regeneron Pharmaceuticals report earnings next?
Regeneron Pharmaceuticals is expected to report on Oct 28, 2026, before the market opens (38 days away). Analysts expect earnings of $15.99 per share on revenue of $4.54B. Regeneron Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 6% on average across the report.
What is Regeneron Pharmaceuticals’s 52-week high and low?
Regeneron Pharmaceuticals’s 52-week high is $859.34 and its 52-week low is $541.00; it closed at $784.85 on Sep 18, 2026, +34.0% over the past year.
Is Regeneron Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, gekkoindex, fair value, smart money and earnings risk) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Regeneron Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.